Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nepidermin
- Development stage
- Phase 3
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intralesional, Topical
01
Overview
Nepidermin is a recombinant form of human epidermal growth factor (EGF), also known as rhEGF. It acts as an agonist of the epidermal growth factor receptor (EGFR), stimulating cell proliferation, differentiation, and regeneration. Nepidermin is primarily used as a cicatrizant to promote wound healing, especially in diabetic foot ulcers, but it has also been marketed for wounds and alopecia. The drug was originally developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB) and has been marketed under various trade names since 2006. It is administered via intralesional injection or topically[1][5][6][7].
- Brand names
- Heberprot-PEasyefGenesoftKang He SuRegen-D
- Other names
- nepiderminrecombinant human epidermal growth factor
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on nepidermin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nepidermin.